Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

Recruiting

Phase 2

Targeted TherapiesStudy of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

Sponsor:

AbbVie

Code:

NCT06548542

Conditions

Crohn's Disease

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Risankizumab

Lutikizumab

ABBV-382

Risankizumab

ABBV-382

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-25. This information was provided to ClinicalTrials.gov by AbbVie on 2025-05-30.